PureTech Health PLC PRTC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category
PureTech Founded Entity Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer
Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer
PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026
Trading Information
- Previous Close Price
- GBX118.20
- Day Range
- GBX117.00–118.20
- 52-Week Range
- GBX106.60–143.60
- Bid/Ask
- GBX117.00 / GBX118.00
- Shares Outstanding
- 245.18M
- Market Cap
- GBX28.75B
- Volume/Avg
- 91,425 / 653,793
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 62.19
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 62
Valuation
Metric | PRTC |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.01 |
Price/Sales | 62.19 |
Price/Cash Flow | — |
Price/Earnings
PRTC
Financial Strength
Metric | PRTC |
|---|---|
Quick Ratio | 4.40 |
Current Ratio | 4.60 |
Interest Coverage | 0.94 |
Quick Ratio
PRTC
Profitability
Metric | PRTC |
|---|---|
Return on Assets (Normalized) | −44.94% |
Return on Equity (Normalized) | −72.18% |
Return on Invested Capital (Normalized) | −57.62% |
Return on Assets
PRTC
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|bR<rn?$ | LOCK|tf!f | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<pM<wD< | LOCK|$TwY | $99B | |||
| Moderna Inc MRNA | LOCK|!^!^r!q | LOCK|k$C | $87B | |||
| argenx SE ADR ARGX | LOCK|fwh?LC$ | LOCK|$> | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|x#f$q% | LOCK|x< | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Wg^Q$q@ | LOCK|yvT^f | $31B | |||
| Incyte Corp INCY | LOCK|yN!J$h | LOCK|Vf< | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|BK&w&Bj | LOCK|SxnX& | $21B | |||
| BioNTech SE ADR BNTX | LOCK|wh$&bM | LOCK|fR | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|P<?>!< | LOCK|$q | $15B |